Pharsight

Drugs facing NCE-1 in 2024

1. List of Avycaz drug patents

AVYCAZ's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7112592 ALLERGAN Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents
Jan, 2026

(2 years from now)

US8471025 ALLERGAN Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt
Aug, 2031

(8 years from now)

US9695122 ALLERGAN Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(9 years from now)

US8969566 ALLERGAN Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(9 years from now)

US9284314 ALLERGAN Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7612087 ALLERGAN Heterocyclic compounds as inhibitors of beta-lactamases
Nov, 2026

(3 years from now)

US8835455 ALLERGAN Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt
Oct, 2030

(7 years from now)

Do you want to check out AVYCAZ patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 25, 2020
New Patient Population (NPP) Dec 20, 2025
Generating Antibiotic Incentives Now (GAIN) Feb 25, 2025

Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient

NCE-1 date: 2024-02-26

Market Authorisation Date: 25 February, 2015

Treatment: A method of treating bacterial infections in complicated intra-abdominal infection and complicated urinary tract infection, including pyelonephritis, patients comprising administering a bactericidally...

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

AVYCAZ family patents

22

United States

9

China

9

Japan

8

European Union

7

Brazil

7

Korea, Republic of

6

Spain

5

Hong Kong

5

France

5

Israel

5

Australia

4

Denmark

4

Poland

4

Russia

4

Canada

4

Argentina

4

Portugal

4

Mexico

4

Slovenia

3

Malaysia

3

Norway

3

Cyprus

3

Taiwan

3

Costa Rica

3

Hungary

2

Austria

2

Turkey

2

Germany

YU

2

Yugoslavia

2

Ukraine

2

Morocco

EA

2

EA

OA

2

OA

2

ME

2

New Zealand

2

Croatia

2

Ecuador

2

South Africa

1

Uruguay

AP

1

AP

1

Czech Republic

1

United Kingdom

1

Estonia

1

Singapore

1

Belgium

1

Peru

1

Chile

1

Jordan

1

Algeria

1

Bulgaria

1

Netherlands

1

Slovakia

1

Colombia

1

Lithuania

1

Tunisia

2. List of Ayvakit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9944651 BLUEPRINT MEDICINES Compositions useful for treating disorders related to kit
Oct, 2034

(11 years from now)

US9200002 BLUEPRINT MEDICINES Compositions useful for treating disorders related to KIT
Oct, 2034

(11 years from now)

US9994575 BLUEPRINT MEDICINES Compositions useful for treating disorders related to kit
Oct, 2034

(11 years from now)

Do you want to check out AYVAKIT patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 9, 2025
New Indication (I) Jun 16, 2024
Orphan Drug Exclusivity (ODE) Jan 9, 2027

Drugs and Companies using AVAPRITINIB ingredient

NCE-1 date: 2024-01-10

Market Authorisation Date: 09 January, 2020

Treatment: Treatment of unresectable or metastatic gastrointestinal stromal tumor (gist) harboring a platelet-derived growth factor receptor alpha (pdgfra) exon 18 mutation; Treatment of advanced systemic mastoc...

Dosage: TABLET;ORAL

More Information on Dosage

AYVAKIT family patents

9

United States

3

Hungary

2

Spain

2

Poland

2

China

2

Japan

2

Portugal

2

Lithuania

2

European Union

1

Uruguay

1

Hong Kong

1

Philippines

1

Denmark

1

RS

1

Russia

1

Brazil

1

Canada

1

Singapore

1

Argentina

1

Norway

1

New Zealand

1

Croatia

1

Korea, Republic of

1

Cyprus

1

Israel

1

Taiwan

1

Mexico

1

Australia

1

Netherlands

1

South Africa

1

Slovenia

3. List of Barhemsys drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10525033 ACACIA Use of amisulpride as an anti-emetic
Mar, 2031

(7 years from now)

US9889118 ACACIA Use of amisulpride as an anti-emetic
Mar, 2031

(7 years from now)

US9545426 ACACIA Use of amisulpride as an anti-emetic
Mar, 2031

(7 years from now)

US9084765 ACACIA Use of amisulpride as an anti-emetic
Feb, 2034

(10 years from now)

US11357753 ACACIA Rescue treatment of post operative nausea and vomiting
Feb, 2038

(14 years from now)

Do you want to check out BARHEMSYS patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 26, 2025

Drugs and Companies using AMISULPRIDE ingredient

NCE-1 date: 2024-02-27

Market Authorisation Date: 26 February, 2020

Treatment: Treatment of post-operative nausea and vomiting; Prevention of post-operative nausea and vomiting

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

BARHEMSYS family patents

11

United States

4

United Kingdom

4

European Union

3

Spain

3

Denmark

3

RS

3

Poland

3

Japan

3

Croatia

3

Cyprus

3

Israel

3

Portugal

3

Mexico

3

Slovenia

2

China

2

Brazil

2

Canada

EA

2

EA

2

San Marino

2

Korea, Republic of

2

Australia

1

Hong Kong

1

Norway

1

New Zealand

1

Lithuania

1

Hungary

4. List of Byfavo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10472365 ACACIA Short-acting benzodiazepine salts and their polymorphic forms
Jul, 2027

(4 years from now)

US9777007 ACACIA Short-acting benzodiazepine salts and their polymorphic forms
Jul, 2027

(4 years from now)

US9914738 ACACIA Short-acting benzodiazepine salts and their polymorphic forms
Jul, 2027

(4 years from now)

US10961250 ACACIA Short-acting benzodiazepine salts and their polymorphic forms
Jul, 2027

(4 years from now)

US10195210 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam)
Nov, 2031

(8 years from now)

US10342800 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam)
Nov, 2031

(8 years from now)

US10722522 ACACIA Dosing regimen for sedation with CNS 7056 (remimazolam)
Nov, 2031

(8 years from now)

US9737547 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam)
Nov, 2031

(8 years from now)

US10052334 ACACIA Dosing regimen for sedation with CNS 7056 (remimazolam)
Nov, 2031

(8 years from now)

US9827251 ACACIA Dosing regimen for sedation with CNS 7056 (remimazolam)
Nov, 2031

(8 years from now)

US9561236 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam)
Apr, 2033

(9 years from now)

Do you want to check out BYFAVO patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 6, 2025

Drugs and Companies using REMIMAZOLAM BESYLATE ingredient

NCE-1 date: 2024-10-06

Market Authorisation Date: 06 October, 2020

Treatment: Use of remimazolam for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

BYFAVO family patents

16

United States

8

European Union

5

China

4

Hong Kong

4

Korea, Republic of

3

United Kingdom

3

Japan

2

Spain

2

Denmark

2

Poland

2

Portugal

2

Australia

2

Slovenia

1

Austria

1

RS

1

Germany

1

Russia

1

Brazil

1

Canada

EA

1

EA

1

Croatia

1

Mexico

1

Lithuania

1

Hungary

5. List of Dayvigo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8268848 EISAI INC Cyclopropane compound
Sep, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10188652 EISAI INC Compositions and methods for treating insomnia
Oct, 2035

(12 years from now)

Do you want to check out DAYVIGO patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 7, 2025

Drugs and Companies using LEMBOREXANT ingredient

NCE-1 date: 2024-04-07

Market Authorisation Date: 07 April, 2020

Treatment: Treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance

Dosage: TABLET;ORAL

More Information on Dosage

DAYVIGO family patents

8

United States

5

Japan

3

Singapore

2

Spain

2

Russia

2

China

2

Brazil

2

Canada

2

Korea, Republic of

2

Israel

2

Mexico

2

Australia

2

European Union

1

Hong Kong

1

Malaysia

1

Denmark

1

RS

1

Poland

1

Ukraine

1

Morocco

1

Argentina

1

New Zealand

1

Croatia

1

Cyprus

1

Peru

1

Chile

1

Portugal

1

Taiwan

1

Jordan

1

Colombia

1

Tunisia

1

Slovenia

6. List of Detectnet drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10383961 RADIOMEDIX PET tracer for imaging of neuroendocrine tumors
Aug, 2032

(9 years from now)

US10159759 RADIOMEDIX Pet tracer for imaging of neuroendocrine tumors
Aug, 2032

(9 years from now)

US11160888 RADIOMEDIX PET tracer for imaging of neuroendocrine tumors
Aug, 2032

(9 years from now)

Do you want to check out DETECTNET patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 3, 2025
Orphan Drug Exclusivity (ODE) Sep 3, 2027

Drugs and Companies using COPPER DOTATATE CU-64 ingredient

NCE-1 date: 2024-09-03

Market Authorisation Date: 03 September, 2020

Treatment: Use of cu-64 dotatate with positron emission tomography (pet) for localization of somatostatin receptor positive neuroendocrine tumors (nets) in adult patients

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

DETECTNET family patents

6

United States

4

Denmark

2

Poland

2

Spain

2

Hungary

2

European Union

7. List of Dojolvi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186344 ULTRAGENYX PHARM INC Glycogen or polysaccharide storage disease treatment method
Jul, 2025

(2 years from now)

US8697748 ULTRAGENYX PHARM INC Glycogen or polysaccharide storage disease treatment method
Oct, 2025

(2 years from now)

Do you want to check out DOJOLVI patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 30, 2027
New Chemical Entity Exclusivity (NCE) Jun 30, 2025

Drugs and Companies using TRIHEPTANOIN ingredient

NCE-1 date: 2024-06-30

Market Authorisation Date: 30 June, 2020

Treatment: NA

Dosage: LIQUID;ORAL

More Information on Dosage

DOJOLVI family patents

11

United States

3

Canada

2

Mexico

2

European Union

8. List of Evrysdi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9586955 GENENTECH INC Compounds for treating spinal muscular atrophy
Feb, 2033

(9 years from now)

US9969754 GENENTECH INC Compounds for treating spinal muscular atrophy
May, 2035

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11534444 GENENTECH INC Treatment of SMA
Oct, 2038

(15 years from now)

Do you want to check out EVRYSDI patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) May 27, 2029
New Chemical Entity Exclusivity (NCE) Aug 7, 2025
New Patient Population (NPP) May 27, 2025

Drugs and Companies using RISDIPLAM ingredient

NCE-1 date: 2024-08-07

Market Authorisation Date: 07 August, 2020

Treatment: Treatment of spinal muscular atrophy

Dosage: FOR SOLUTION;ORAL

More Information on Dosage

EVRYSDI family patents

12

United States

5

European Union

EA

4

EA

4

Korea, Republic of

4

Israel

3

Philippines

3

China

3

Morocco

3

Singapore

3

Japan

3

Taiwan

3

Australia

3

Hungary

2

Spain

2

Denmark

2

Poland

2

Brazil

2

Canada

2

Ukraine

2

Argentina

2

New Zealand

2

Peru

2

Chile

2

Mexico

2

Costa Rica

1

Hong Kong

1

Turkey

1

RS

1

Norway

1

Croatia

1

Portugal

1

Ecuador

1

Netherlands

1

South Africa

1

Colombia

1

Lithuania

1

Slovenia

9. List of Gavreto drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10030005 GENENTECH INC Inhibitors of RET
Nov, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11273160 GENENTECH INC RET inhibitor for use in treating cancer having a RET alteration
Apr, 2039

(15 years from now)

Do you want to check out GAVRETO patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 4, 2025
Orphan Drug Exclusivity (ODE) Sep 4, 2027

Drugs and Companies using PRALSETINIB ingredient

NCE-1 date: 2024-09-04

Market Authorisation Date: 04 September, 2020

Treatment: Treatment of adult patients with metastatic rearranged during transfection (ret) fusion-positive non-small cell lung cancer (nsclc) as detected by an fda approved test; Treatment of adult and pediatri...

Dosage: CAPSULE;ORAL

More Information on Dosage

GAVRETO family patents

19

United States

6

Japan

3

China

3

Israel

3

European Union

2

Brazil

2

Canada

2

Singapore

2

Korea, Republic of

2

Chile

2

Australia

1

Hong Kong

1

Philippines

1

Russia

1

Morocco

1

Argentina

EA

1

EA

1

Peru

1

Taiwan

1

Mexico

1

Costa Rica

1

Ecuador

1

South Africa

1

Saudi Arabia

10. List of Gemtesa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8653260 UROVANT Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
Apr, 2029

(5 years from now)

US8247415 UROVANT Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists
Dec, 2030

(7 years from now)

Do you want to check out GEMTESA patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 23, 2025

Drugs and Companies using VIBEGRON ingredient

NCE-1 date: 2024-12-23

Market Authorisation Date: 23 December, 2020

Treatment: Treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency

Dosage: TABLET;ORAL

More Information on Dosage

GEMTESA family patents

8

United States

3

Japan

3

Korea, Republic of

2

Dominican Republic

2

China

2

Costa Rica

1

Spain

1

Austria

1

Hong Kong

1

Denmark

1

RS

1

Poland

1

Brazil

1

Canada

1

Ukraine

1

Singapore

1

Morocco

1

Argentina

EA

1

EA

1

ME

1

Nicaragua

1

New Zealand

1

Honduras

1

Croatia

1

Cyprus

1

Peru

1

Chile

1

Israel

1

Portugal

1

El Salvador

1

Taiwan

1

Georgia

1

Mexico

1

Australia

1

Ecuador

1

South Africa

1

Colombia

1

Tunisia

1

Slovenia

1

European Union

11. List of Imcivree drug patents

IMCIVREE's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9458195 RHYTHM Melanocortin receptor ligands
Oct, 2027

(4 years from now)

US8039435 RHYTHM Melanocortin receptor ligands
Oct, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11129869 RHYTHM Pharmaceutical compositions
Jul, 2034

(11 years from now)

Do you want to check out IMCIVREE patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 16, 2029
New Chemical Entity Exclusivity (NCE) Nov 25, 2025
New Indication (I) Jun 16, 2025

Drugs and Companies using SETMELANOTIDE ACETATE ingredient

NCE-1 date: 2024-11-25

Market Authorisation Date: 25 November, 2020

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

IMCIVREE family patents

16

United States

8

European Union

7

Japan

5

Spain

5

Denmark

5

Poland

5

China

5

Israel

5

Portugal

5

Australia

4

Hong Kong

4

Russia

4

Canada

4

Hungary

3

Korea, Republic of

2

New Zealand

2

Netherlands

1

Brazil

1

Singapore

1

Slovenia

12. List of Inqovi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9567363 OTSUKA Certain compounds, compositions and methods
Oct, 2028

(5 years from now)

US8268800 OTSUKA Certain compounds, compositions and methods
Aug, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8618075 OTSUKA Certain compounds, compositions and methods
Oct, 2028

(5 years from now)

Do you want to check out INQOVI patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 7, 2025
Orphan Drug Exclusivity (ODE) Jul 7, 2027

Drugs and Companies using CEDAZURIDINE; DECITABINE ingredient

NCE-1 date: 2024-07-07

Market Authorisation Date: 07 July, 2020

Treatment: Method for inhibiting cytidine deaminase by administering cedazuridine; Method for inhibiting degradation of a cda substrate by administering cedazuridine; Treatment of chronic myelomonocytic leukemia...

Dosage: TABLET;ORAL

More Information on Dosage

INQOVI family patents

6

United States

2

Spain

2

Japan

2

European Union

1

Hong Kong

1

Austria

1

Malaysia

1

Denmark

1

RS

1

Poland

1

China

1

Brazil

1

Canada

1

Ukraine

EA

1

EA

1

ME

1

Nicaragua

1

New Zealand

1

Croatia

1

Korea, Republic of

1

Guatemala

1

Cyprus

1

Israel

1

Portugal

1

Taiwan

1

Jordan

1

Mexico

1

Australia

1

Costa Rica

1

Ecuador

1

South Africa

1

Colombia

1

Saudi Arabia

1

Slovenia

13. List of Isturisa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8835646 RECORDATI RARE Organic compounds
Aug, 2026

(3 years from now)

US8314097 RECORDATI RARE Organic compounds
Mar, 2029

(5 years from now)

US9434754 RECORDATI RARE Use of an adrenal hormone-modifying agent
Jan, 2031

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8609862 RECORDATI RARE Use of an adrenal hormone-modifying agent
Jan, 2031

(7 years from now)

US10143680 RECORDATI RARE Pharmaceutical dosage forms
Jul, 2035

(12 years from now)

US10709691 RECORDATI RARE Pharmaceutical dosage forms
Oct, 2035

(12 years from now)

Do you want to check out ISTURISA patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 6, 2025
Orphan Drug Exclusivity (ODE) Mar 6, 2027

Drugs and Companies using OSILODROSTAT PHOSPHATE ingredient

NCE-1 date: 2024-03-06

Market Authorisation Date: 06 March, 2020

Treatment: Cushing's disease

Dosage: TABLET;ORAL

More Information on Dosage

ISTURISA family patents

16

United States

8

Japan

7

European Union

5

China

5

Korea, Republic of

4

Spain

4

Mexico

3

Denmark

3

Poland

3

Canada

3

Singapore

EA

3

EA

3

Croatia

3

Cyprus

3

Peru

3

Israel

3

Portugal

3

Taiwan

3

Australia

3

Lithuania

3

Tunisia

3

Slovenia

3

Hungary

2

Philippines

2

Brazil

2

Morocco

2

Argentina

2

Norway

2

New Zealand

2

Chile

2

Ecuador

2

South Africa

IB

1

IB

1

Hong Kong

1

Malaysia

1

Turkey

1

RS

1

Russia

1

Ukraine

1

ME

1

Guatemala

1

Jordan

1

Netherlands

1

Luxembourg

14. List of Klisyri drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8236799 ALMIRALL Biaryl compositions and methods for modulating a kinase cascade
Dec, 2025

(2 years from now)

US8980890 ALMIRALL Compositions and methods of treating cell proliferation disorders
Dec, 2025

(2 years from now)

US7300931 ALMIRALL Compositions for treating cell proliferation disorders
Feb, 2026

(2 years from now)

US7851470 ALMIRALL Composition and methods for modulating a kinase cascade
Feb, 2029

(5 years from now)

US10669236 ALMIRALL Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
Sep, 2038

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10323001 ALMIRALL Compositions for modulating a kinase cascade and methods of use thereof
Dec, 2027

(4 years from now)

US11497750 ALMIRALL Methods of treating and/or preventing actinic keratosis
Mar, 2038

(14 years from now)

US10617693 ALMIRALL Methods of treating and/or preventing actinic keratosis
Mar, 2038

(14 years from now)

Do you want to check out KLISYRI patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 14, 2025

Drugs and Companies using TIRBANIBULIN ingredient

NCE-1 date: 2024-12-14

Market Authorisation Date: 14 December, 2020

Treatment: Topical treatment of actinic keratosis of the face or scalp

Dosage: OINTMENT;TOPICAL

More Information on Dosage

KLISYRI family patents

54

United States

12

Japan

9

China

6

Canada

6

Australia

6

European Union

4

Spain

4

Denmark

4

Korea, Republic of

4

Israel

4

Taiwan

3

Hong Kong

3

Russia

3

Brazil

2

Singapore

2

Cyprus

2

Mexico

1

Austria

1

Malaysia

1

Poland

1

Portugal

1

Netherlands

1

South Africa

1

Slovenia

1

Hungary

15. List of Koselugo drug patents

KOSELUGO's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8178693 ASTRAZENECA N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2023

(2 months ago)

US7425637 ASTRAZENECA N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2024

(9 months from now)

US9156795 ASTRAZENECA Hydrogen sulfate salt
Dec, 2026

(3 years from now)

US9562017 ASTRAZENECA Hydrogen sulfate salt
Dec, 2026

(3 years from now)

Do you want to check out KOSELUGO patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 10, 2025
Orphan Drug Exclusivity (ODE) Apr 10, 2027

Drugs and Companies using SELUMETINIB SULFATE ingredient

NCE-1 date: 2024-04-10

Market Authorisation Date: 10 April, 2020

Treatment: Treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (nf1) who have symptomatic, inoperable plexiform neurofibromas (pn)

Dosage: CAPSULE;ORAL

More Information on Dosage

KOSELUGO family patents

24

United States

7

Spain

7

China

7

European Union

6

Poland

6

Japan

5

Iceland

5

Denmark

5

Brazil

5

Argentina

5

Korea, Republic of

5

Cyprus

5

Israel

5

Portugal

5

Taiwan

5

Slovenia

4

Hong Kong

4

Dominican Republic

4

Australia

3

Russia

3

Canada

3

Singapore

3

Mexico

3

South Africa

3

Hungary

2

Ukraine

2

New Zealand

2

Chile

2

Netherlands

2

Lithuania

1

Panama

1

Austria

1

Malaysia

1

RS

1

Germany

1

Norway

1

Croatia

1

Belgium

1

Ecuador

1

Luxembourg

16. List of Myfembree drug patents

MYFEMBREE's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7300935 MYOVANT SCIENCES Thienopyrimidine compounds and use thereof
Jan, 2024

(8 months from now)

US8058280 MYOVANT SCIENCES Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof
Jan, 2024

(8 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9346822 MYOVANT SCIENCES Thienopyrimidine compounds and use thereof
Feb, 2024

(8 months from now)

US11033551 MYOVANT SCIENCES Methods of treating uterine fibroids
Sep, 2037

(14 years from now)

Do you want to check out MYFEMBREE patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 18, 2025
New Product (NP) May 26, 2024
M (M) Jan 27, 2026
New Indication (I) Aug 5, 2025

Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient

NCE-1 date: 2024-12-18

Market Authorisation Date: 26 May, 2021

Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women

Dosage: TABLET;ORAL

More Information on Dosage

MYFEMBREE family patents

20

United States

8

Japan

8

European Union

5

Australia

4

China

4

Canada

4

Israel

3

Brazil

3

Morocco

3

Argentina

EA

3

EA

3

New Zealand

3

Mexico

2

Spain

2

Denmark

2

Poland

2

Norway

2

Portugal

2

Lithuania

2

Slovenia

2

Hungary

1

Hong Kong

1

Moldova, Republic of

1

RS

1

Russia

1

Croatia

1

Korea, Republic of

1

Cyprus

1

Taiwan

1

Netherlands

1

South Africa

1

Colombia

17. List of Nexletol drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7335799 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2025

(2 years from now)

US11613511 ESPERION THERAPS INC Methods of making bempedoic acid and compositions of the same
Jun, 2040

(17 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10941095 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(6 months from now)

US9000041 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(6 months from now)

US9624152 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(6 months from now)

US10118881 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(6 months from now)

US8497301 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(6 months from now)

Do you want to check out NEXLETOL patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 21, 2025

Drugs and Companies using BEMPEDOIC ACID ingredient

NCE-1 date: 2024-02-22

Market Authorisation Date: 21 February, 2020

Treatment: Use of nexletol as an adjunct to diet and maximally tolerated statin therapy to lower ldl-c in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular dise...

Dosage: TABLET;ORAL

More Information on Dosage

NEXLETOL family patents

25

United States

3

Spain

3

European Union

2

Mexico

2

Japan

2

Hungary

1

Cyprus

1

Brazil

1

Canada

1

Portugal

1

Slovenia

1

Australia

1

Denmark

18. List of Nexlizet drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7335799 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2025

(2 years from now)

US11613511 ESPERION THERAPS INC Methods of making bempedoic acid and compositions of the same
Jun, 2040

(17 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9624152 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(6 months from now)

US8497301 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(6 months from now)

US9000041 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(6 months from now)

US10118881 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(6 months from now)

US10941095 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(6 months from now)

US10912751 ESPERION THERAPS INC Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
Mar, 2036

(12 years from now)

Do you want to check out NEXLIZET patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 21, 2025
New Product (NP) Feb 26, 2023

Drugs and Companies using BEMPEDOIC ACID; EZETIMIBE ingredient

NCE-1 date: 2024-02-22

Market Authorisation Date: 26 February, 2020

Treatment: Use of nexlizet as an adjunct to diet and maximally tolerated statin therapy for inhibiting cholesterol synthesis to lower ldl-c in adults with heterozygous familial hypercholesterolemia or establishe...

Dosage: TABLET;ORAL

More Information on Dosage

NEXLIZET family patents

31

United States

4

Japan

4

European Union

3

Spain

3

Mexico

3

Australia

2

China

2

Russia

2

Brazil

2

Canada

2

Singapore

2

Hungary

1

Philippines

1

Denmark

1

Ukraine

1

Morocco

1

Korea, Republic of

1

Cyprus

1

Chile

1

Portugal

1

South Africa

1

Slovenia

19. List of Nurtec Odt drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8314117 BIOHAVEN IRELAND CGRP receptor antagonists
Feb, 2031

(7 years from now)

US8759372 BIOHAVEN IRELAND N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta[b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylate salt
Feb, 2033

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11083724 BIOHAVEN IRELAND Rimegepant for CGRP related disorders
Mar, 2039

(15 years from now)

Do you want to check out NURTEC ODT patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 27, 2025
New Indication (I) May 27, 2024

Drugs and Companies using RIMEGEPANT SULFATE ingredient

NCE-1 date: 2024-02-28

Market Authorisation Date: 27 February, 2020

Treatment: Acute treatment of migraine with or without aura in adults; Preventive treatment of episodic migraine in adults

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage

NURTEC ODT family patents

18

United States

6

Japan

6

Korea, Republic of

5

European Union

4

Canada

3

Spain

3

Denmark

3

RS

3

Poland

3

China

3

Brazil

EA

3

EA

3

Croatia

3

Israel

3

Portugal

3

Mexico

3

Australia

3

Lithuania

3

Slovenia

3

Hungary

2

Hong Kong

2

Singapore

2

Argentina

2

Norway

2

Cyprus

1

Philippines

1

New Zealand

1

San Marino

1

Peru

1

Chile

1

Taiwan

1

Netherlands

1

South Africa

1

Colombia

1

Tunisia

20. List of Olinvyk drug patents

OLINVYK's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8835488 TREVENA Opioid receptor ligands and methods of using and making same
Mar, 2032

(8 years from now)

US11077098 TREVENA Opioid receptor ligands and methods of using and making same
Mar, 2032

(8 years from now)

US9309234 TREVENA Opioid receptor ligands and methods of using and making same
Mar, 2032

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9642842 TREVENA Opioid receptor ligands and methods of using and making same
Mar, 2032

(8 years from now)

Do you want to check out OLINVYK patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 30, 2025

Drugs and Companies using OLICERIDINE ingredient

NCE-1 date: 2024-10-30

Market Authorisation Date: 30 October, 2020

Treatment: Management of acute pain by intravenous injection

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

OLINVYK family patents

11

United States

5

Japan

4

Israel

3

Korea, Republic of

3

European Union

2

Spain

2

Denmark

2

Poland

2

New Zealand

2

Portugal

2

Australia

2

Hungary

1

Hong Kong

1

RS

1

China

1

Brazil

1

Canada

EA

1

EA

1

ME

1

Croatia

1

Cyprus

1

Lithuania

1

Slovenia

21. List of Ongentys drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8907099 NEUROCRINE Nitrocatechol derivatives as COMT inhibitors
May, 2027

(3 years from now)

US8168793 NEUROCRINE Nitrocatechol derivatives as COMT inhibitors
Apr, 2029

(5 years from now)

US9630955 NEUROCRINE Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor
Dec, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9550759 NEUROCRINE Nitrocatechol derivatives as COMT inhibitors
Jul, 2026

(3 years from now)

US9745290 NEUROCRINE Dosage regimen for COMT inhibitors
Oct, 2027

(4 years from now)

US8524746 NEUROCRINE Dosage regimen for COMT inhibitors
Jul, 2029

(6 years from now)

US10583130 NEUROCRINE Pharmaceutical formulations compromising nitrocatechol derivatives and methods of making thereof
Mar, 2030

(6 years from now)

US10071085 NEUROCRINE Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
Mar, 2030

(6 years from now)

US10357468 NEUROCRINE Medicaments for slowing Parkinson's disease
May, 2035

(12 years from now)

Do you want to check out ONGENTYS patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 24, 2025

Drugs and Companies using OPICAPONE ingredient

NCE-1 date: 2024-04-24

Market Authorisation Date: 24 April, 2020

Treatment: Method of inhibiting comt in the periphery; Method of treating parkinson's disease; Method of reducing o-methylation of l-dopa; Adjunctive treatment to levodopa/carbidopa in patients with parkinson's ...

Dosage: CAPSULE;ORAL

More Information on Dosage

ONGENTYS family patents

26

United States

10

Japan

10

European Union

9

Portugal

7

Korea, Republic of

5

Spain

5

Denmark

5

China

5

Russia

5

Canada

4

Poland

4

Brazil

4

Australia

4

Hungary

3

Argentina

3

Norway

3

Cyprus

3

Slovenia

3

Mexico

3

United Kingdom

IB

2

IB

2

Croatia

2

Israel

2

South Africa

2

Lithuania

1

Hong Kong

1

Turkey

1

RS

1

Ukraine

1

New Zealand

1

Netherlands

1

Luxembourg

22. List of Orgovyx drug patents

ORGOVYX's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7300935 MYOVANT SCIENCES Thienopyrimidine compounds and use thereof
Jan, 2024

(8 months from now)

US8058280 MYOVANT SCIENCES Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof
Jan, 2024

(8 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8735401 MYOVANT SCIENCES Thienopyrimidine compounds and use thereof
Feb, 2024

(8 months from now)

US10350170 MYOVANT SCIENCES Solid preparation
Feb, 2036

(12 years from now)

US10449191 MYOVANT SCIENCES Treatment of prostate cancer
Sep, 2037

(14 years from now)

US11583526 MYOVANT SCIENCES Treatment of prostate cancer
Sep, 2037

(14 years from now)

US10786501 MYOVANT SCIENCES Treatment of prostate cancer
Sep, 2037

(14 years from now)

Do you want to check out ORGOVYX patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 18, 2025

Drugs and Companies using RELUGOLIX ingredient

NCE-1 date: 2024-12-18

Market Authorisation Date: 18 December, 2020

Treatment: Treatment of adult patients with advanced prostate cancer that is sex-hormone-dependent; Treatment of adult patients with advanced prostate cancer

Dosage: TABLET;ORAL

More Information on Dosage

ORGOVYX family patents

23

United States

11

Japan

9

European Union

6

Australia

5

China

5

Canada

5

Israel

4

Brazil

4

New Zealand

4

Mexico

3

Morocco

3

Argentina

EA

3

EA

2

Spain

2

Denmark

2

Poland

2

Norway

2

Portugal

2

Taiwan

2

Lithuania

2

Slovenia

2

Hungary

1

Hong Kong

1

Malaysia

1

Moldova, Republic of

1

RS

1

Russia

1

Croatia

1

Korea, Republic of

1

Cyprus

1

Netherlands

1

South Africa

1

Colombia

23. List of Orladeyo drug patents

Can you believe ORLADEYO received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10329260 BIOCRYST Human plasma kallikrein inhibitors
Mar, 2035

(11 years from now)

US10125102 BIOCRYST Human plasma kallikrein inhibitors
Apr, 2035

(11 years from now)

US10662160 BIOCRYST Crystalline salts of a plasma kallikrein inhibitor
Nov, 2039

(16 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11230530 BIOCRYST Human plasma kallikrein inhibitors
Mar, 2035

(11 years from now)

US10689346 BIOCRYST Human plasma kallikrein inhibitors
Mar, 2035

(11 years from now)

US11618733 BIOCRYST Crystalline salts of a plasma kallikrein inhibitor
Nov, 2039

(16 years from now)

US11117867 BIOCRYST Crystalline salts of a plasma kallikrein inhibitor
Nov, 2039

(16 years from now)

Do you want to check out ORLADEYO patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 3, 2027
New Chemical Entity Exclusivity (NCE) Dec 3, 2025

Drugs and Companies using BEROTRALSTAT HYDROCHLORIDE ingredient

NCE-1 date: 2024-12-03

Market Authorisation Date: 03 December, 2020

Treatment: Prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and pediatric patients 12 years of age and older; Prophylaxis to prevent attacks of hereditary angiodema (hae) in adults and ped...

Dosage: CAPSULE;ORAL

More Information on Dosage

ORLADEYO family patents

16

United States

4

Japan

4

Australia

3

China

3

Canada

3

Singapore

3

Morocco

EA

3

EA

3

Israel

3

Lithuania

3

European Union

2

Philippines

2

Denmark

2

RS

2

Poland

2

Brazil

2

New Zealand

2

Croatia

2

Korea, Republic of

2

Hungary

1

Uruguay

1

Spain

1

Argentina

1

Norway

1

Peru

1

Chile

1

Portugal

1

Taiwan

1

Mexico

1

Netherlands

1

Colombia

1

Slovenia

24. List of Oxlumo drug patents

Can you believe OXLUMO received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10131907 ALNYLAM PHARMS INC Glycoconjugates of RNA interference agents
Aug, 2028

(5 years from now)

US8828956 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(5 years from now)

US8106022 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2029

(6 years from now)

US11060093 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(11 years from now)

US10465195 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(11 years from now)

US10487330 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(11 years from now)

US9828606 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(11 years from now)

US10612027 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(12 years from now)

US11401517 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(12 years from now)

US10612024 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(12 years from now)

US11446380 ALNYLAM PHARMS INC Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
Oct, 2035

(12 years from now)

US10478500 ALNYLAM PHARMS INC Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression
Oct, 2035

(12 years from now)

US11261447 ALNYLAM PHARMS INC Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
Nov, 2038

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10435692 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(11 years from now)

Do you want to check out OXLUMO patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Oct 6, 2029
New Chemical Entity Exclusivity (NCE) Nov 23, 2025
New Indication (I) Oct 6, 2025

Drugs and Companies using LUMASIRAN SODIUM ingredient

NCE-1 date: 2024-11-23

Market Authorisation Date: 23 November, 2020

Treatment: Treatment of primary hyperoxaluria type 1 (ph1)

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

OXLUMO family patents

68

United States

20

Japan

16

European Union

12

Canada

9

Australia

5

China

5

Singapore

4

Israel

4

Lithuania

4

Hungary

3

Spain

3

Denmark

2

RS

2

Poland

EA

2

EA

2

Norway

2

Croatia

2

Korea, Republic of

2

Portugal

2

Taiwan

2

Jordan

2

Mexico

2

Slovenia

1

Uruguay

1

Dominican Republic

1

Philippines

1

Malaysia

1

Brazil

1

Ukraine

1

Morocco

1

Argentina

1

Peru

1

Chile

1

Costa Rica

1

Ecuador

1

South Africa

1

Colombia

1

Luxembourg

1

Tunisia

25. List of Pemazyre drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9611267 INCYTE CORP Substituted tricyclic compounds as FGFR inhibitors
Jan, 2035

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10131667 INCYTE CORP Substituted tricyclic compounds as FGFR inhibitors
Jun, 2033

(10 years from now)

US11466004 INCYTE CORP Solid forms of an FGFR inhibitor and processes for preparing the same
May, 2039

(15 years from now)

Do you want to check out PEMAZYRE patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 17, 2025
Orphan Drug Exclusivity (ODE) Aug 26, 2029
New Indication (I) Aug 26, 2025

Drugs and Companies using PEMIGATINIB ingredient

NCE-1 date: 2024-04-17

Market Authorisation Date: 17 April, 2020

Treatment: For the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement; Treatment of p...

Dosage: TABLET;ORAL

More Information on Dosage

PEMAZYRE family patents

15

United States

6

Japan

5

Israel

5

European Union

4

Philippines

4

China

4

Argentina

4

Korea, Republic of

4

Australia

4

Lithuania

4

Hungary

3

Spain

3

Denmark

3

RS

3

Poland

3

Canada

3

Singapore

EA

3

EA

3

New Zealand

3

Croatia

3

Peru

3

Chile

3

Portugal

3

Taiwan

3

Slovenia

2

Malaysia

2

Brazil

2

Ukraine

2

ME

2

Cyprus

2

Costa Rica

2

Ecuador

2

Colombia

IB

1

IB

1

Hong Kong

1

Morocco

1

Norway

1

Mexico

1

Netherlands

26. List of Pizensy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10806743 BRAINTREE LABS Method of administering lactitol to reduce plasma concentration of lactitol
May, 2037

(13 years from now)

Do you want to check out PIZENSY patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 12, 2025

Drugs and Companies using LACTITOL ingredient

NCE-1 date: 2024-02-13

Market Authorisation Date: 12 February, 2020

Treatment: Method of treating chronic idiopathic constipation in adult patients.

Dosage: FOR SOLUTION;ORAL

More Information on Dosage

27. List of Qinlock drug patents

Can you believe QINLOCK received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8188113 DECIPHERA PHARMS Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
Jul, 2030

(7 years from now)

US8461179 DECIPHERA PHARMS Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
Jun, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE48731 DECIPHERA PHARMS Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
Jun, 2032

(9 years from now)

US11433056 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(17 years from now)

US11534432 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(17 years from now)

US11529336 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(17 years from now)

US11344536 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(17 years from now)

US11426390 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(17 years from now)

US10966966 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(17 years from now)

US11266635 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(17 years from now)

US11576904 DECIPHERA PHARMS NA
Aug, 2040

(17 years from now)

US11576903 DECIPHERA PHARMS NA
Dec, 2040

(17 years from now)

US11612591 DECIPHERA PHARMS NA
Dec, 2040

(17 years from now)

US11395818 DECIPHERA PHARMS Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
Dec, 2040

(17 years from now)

US11185535 DECIPHERA PHARMS Amorphous kinase inhibitor formulations and methods of use thereof
Dec, 2040

(17 years from now)

Do you want to check out QINLOCK patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 15, 2025
Orphan Drug Exclusivity (ODE) May 15, 2027

Drugs and Companies using RIPRETINIB ingredient

NCE-1 date: 2024-05-15

Market Authorisation Date: 15 May, 2020

Treatment: Treatment of gastrointestinal stromal tumor; Method of treating gastrointestinal stromal tumors in patients suffering from grade 2 or grade 3 myalgia while being administered ripretinib daily; Treatme...

Dosage: TABLET;ORAL

More Information on Dosage

QINLOCK family patents

44

United States

7

China

7

European Union

6

Korea, Republic of

6

Brazil

6

Australia

5

Canada

4

Japan

3

Israel

3

Taiwan

3

Argentina

EA

3

EA

2

Mexico

28. List of Retevmo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10112942 LOXO ONCOLOGY INC Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Oct, 2037

(14 years from now)

US10584124 LOXO ONCOLOGY INC Crystalline forms
Oct, 2038

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10137124 LOXO ONCOLOGY INC Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Oct, 2037

(14 years from now)

US10172851 LOXO ONCOLOGY INC Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Oct, 2037

(14 years from now)

US10786489 LOXO ONCOLOGY INC Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrile
Oct, 2038

(15 years from now)

Do you want to check out RETEVMO patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 8, 2025
Orphan Drug Exclusivity (ODE) Sep 21, 2029

Drugs and Companies using SELPERCATINIB ingredient

NCE-1 date: 2024-05-08

Market Authorisation Date: 08 May, 2020

Treatment: Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant medullary thyroid cancer (mtc) who require systemic therapy; Treatment of adult patients with...

Dosage: CAPSULE;ORAL

More Information on Dosage